** Shares of biotech firm Patrys fall 50% to A$0.003, a record low
** Stock posts biggest intraday pct fall since Nov. 11, 2008
** Co says cancer therapy antibody PAT-DX1 did not pass some parameters in production
** Adds, it will not use the produced batch for planned Phase-1 clinical trial in cancer patients
** Says it will now pivot towards developing therapeutic possibilities for its other antibody, PAT-DX3
** About 24 mln shares change hands, ~28x the 30-day avg volume
** PNB down ~63% YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。